An article published in the Fall 2004 issue of this journal discussed a recently approved drug, Strattera, which is used for children and adults with Attention Deficit Hyperactivity Disorder (ADHD). The advantages and disadvantages of this medication were discussed in detail. However, there are new concerns about the use of Strattera after it has been prescribed to two million people over a four year period. Severe liver injury has been seen in two people in the United States and 41 persons worldwide. Although these numbers appear to be quite small, Eli Lilly and Company states that because of probable underreporting the actual number of affected persons is currently unknown. Parents, teachers, and support personnel should not overreact to these reports, but should be judicious in watching for typical signs of hepatic or liver problems: itchy skin, abdominal pain, yellowing of the eyes and skin, discolored urine, and flu symptoms coupled with nausea. If any of these signs are present following the administration of Strattera, the physician should be contacted immediately. Additionally, parents should discuss this new health risk with the child's physician during routine checkups. This might be especially important for children with other health impairments.